Analysguiden has completed an analysis of Stayble Therapeutics and initiates equity research coverage
February 2022Analysguiden has completed an analysis of Stayble Therapeutics. The analysis is available at the following link: https://www.aktiespararna.se/analysguiden/nyheter/initieringsanalys-stayble-therapeutics-unik-behandling-diskrelaterad-ryggsmarta
“We are focusing on continuing the development of STA363 to offer an effective and alternative treatment for chronic back pain. While we continue to work on our phase 2b study, we also want to take the opportunity to increase the knowledge and understanding of our ambitions regarding the treatment of back pain and talk more about our drug candidate. As a part of this, we have established a partnership with Analysguiden to give investors a better understanding of Stayble Therapeutics,” comments CEO Andreas Gerward.
For more information
Andreas Gerward, CEO Stayble Therapeutics AB
andreas.gerward@stayble.se
+46 730 808 397